Connected hospitals with intelligent messaging In today's hospitals, pacemakers, defibrillators and oximeters are all connected to the internet and share vitals immediately with doctors, in turn speeding response times. Hospitals have technicians, nurses, staff, billing departments, insurance providers, patients and patients' families as stakeholders, each with different requirements of information about the care given to patient. Unified Inbox offers an AI-based unified cloud IoT messaging platform for internet of things devices to connect various stakeholders, giving them the freedom to receive different messages at different frequency, with different senses of urgency in different mediums of their choice. Unified Inbox launched this at Nanyang Polytechnic in Singapore as "CUBE," the IoT-secured messaging gateway for healthcare. The artificial intelligence makes the hospitals connected, giving peace of mind to patients and their loved ones while improving efficiency in the overall hospital management and interaction with all stakeholders.

You don't have to be a gambler to appreciate the complexities of the card game Texas Hold'Em. It involves a strategy that needs to evolve based on the players around the table, it takes a certain amount of intuition, and it doesn't require the player to win every hand. Just a few days ago, an artificial intelligence (AI) algorithm named Libratus beat four professional poker players at a no-limit Texas Hold'Em tournament played out over 20 days. If you have even the slightest understanding of how to write code, you would realize that it is impossible to actually code a software program to do that with such "imperfect information". The AI algorithm did exceptionally well and was utilizing strategies that humans had never used before.

A soft robotic sleeve placed around the heart in a pig model of acute heart failure. The actuators embedded in the sleeve support heart function by mimicking the outer heart muscles that induce the heart to beat. An international team of scientists has developed a soft robotic sleeve that can be implanted on the external surface of the heart to restore blood circulation in pigs (and possibly humans in the future) whose hearts have stopped beating. The device is a silicon-based system with two layers of actuators: one that squeezes circumferentially and one that squeezes diagonally, both designed to mimic the movement of healthy hearts when they beat. Heart failure affects 41 million people worldwide.

Machine learning was undoubtedly one of the hottest topics in radiology last year, with a steady stream of academic research papers highlighting how machine learning, particularly deep learning, can outperform traditional algorithms or manual processes in certain use-cases. Investment in machine learning start-ups also continued, with several companies attracting early stage funding. To date, more than $100m has been invested in start-ups that are developing AI solutions for radiology. Furthermore, commercial activity gained pace, with at least 20 companies exhibiting AI-based products at the RSNA conference towards the end of the year, although most were prototypes and only a handful had regulatory clearance. Whilst the enthusiasm for machine learning is certainly justified, it inevitably raises expectations, potentially to unrealistic levels.

I've always had a lot of respect for veterinarians, because they are masters at solving problems based purely on fuzzy symptoms that their patients cannot explain: where it hurts, how long it's been hurting, and what events led up to the problem. Many times the patients don't even know they are sick. Yet a vet is able to make educated guesses with the data they do have, which often results in successful diagnoses and treatments. Wireless local area networks (WLANs) cannot talk, either, which often forces IT administrators to operate like doctors, listening to wireless users describe symptoms in vague terms: "I can't connect." "Sometimes it works, sometimes it doesn't."

The Arterys Cardio DLTM application is vendor agnostic and was developed using data from several thousand cardiac cases. The software produces editable automated contours, providing precise and consistent ventricular function in seconds. The trained deep learning algorithm was validated as producing results within an expected error range comparable to that of an experienced clinical annotator. This clearance enables Arterys to make use of its unique clinical annotation platform, which collects ground-truth data every time a user views a study on Arterys.com. In the future, the deep learning model can be optimized as new data is collected from all global users.

The first FDA approval for a machine learning application to be used in a clinical setting is a big step forward for AI and machine learning in healthcare and industry as a whole. Arterys's medical imaging platform has been approved to be put into use to help doctors diagnose heart problems. It uses a self-teaching artificial neural network which has learned from 1,000 cases so far, and will continue to improve its knowledge and understanding of how the heart works with each new case it examines. In order to be approved by the US Food and Drug Administration (FDA), it had to pass tests to show it can produce results at least as accurately as humans are currently able to. The key difference though is that Arterys takes an average of 15 seconds to produce a result for one case, which a professional human analyst would expect to spend between 30 minutes to an hour working on. Arterys was founded by Fabien Beckers, John Axerio-Cilies, Albert Hsiao and Shreyas Vasanawala when they met at Stanford University with a shared passion for the transformative potential of machine learning.

The first FDA approval for a machine learning application to be used in a clinical setting is a big step forward for AI and machine learning in healthcare and industry as a whole. Arterys's medical imaging platform has been approved to be put into use to help doctors diagnose heart problems. It uses a self-teaching artificial neural network which has learned from 1,000 cases so far, and will continue to improve its knowledge and understanding of how the heart works with each new case it examines. In order to be approved by the US Food and Drug Administration (FDA), it had to pass tests to show it can produce results at least as accurately as humans are currently able to. The key difference though is that Arterys takes an average of 15 seconds to produce a result for one case, which a professional human analyst would expect to spend between 30 minutes to an hour working on.

The first FDA approval for a machine learning application to be used in a clinical setting is a big step forward for AI and machine learning in healthcare and industry as a whole. Arterys's medical imaging platform has been approved to be put into use to help doctors diagnose heart problems. It uses a self-teaching artificial neural network which has learned from 1,000 cases so far, and will continue to improve its knowledge and understanding of how the heart works with each new case it examines. In order to be approved by the US Food and Drug Administration (FDA), it had to pass tests to show it can produce results at least as accurately as humans are currently able to. The key difference though is that Arterys takes an average of 15 seconds to produce a result for one case, which a professional human analyst would expect to spend between 30 minutes to an hour working on. Arterys was founded by Fabien Beckers, John Axerio-Cilies, Albert Hsiao and Shreyas Vasanawala when they met at Stanford University with a shared passion for the transformative potential of machine learning.

Analyzing queries made to Google, Bing, and other search engines can reveal the potentially dangerous consequences of mixing prescriptions before they are known to the Food and Drug Administration (FDA), according to a new study. Such data mining could even expose medical risks that slip through clinical trials undetected. Pharmaceuticals often have side effects that go unnoticed until they're already available to the public. This is especially true of side effects that emerge when two drugs interact, largely because drug trials try to pinpoint the effects of one drug at a time. Physicians have a few ways to hunt for these hidden risks, such as reports to FDA from doctors, nurses, and patients.